One important takeaway from today's press release is that the lower sensitivity of 85% for the colon cancer screen was obtained on a second set of 138 samples using a different pair of microRNA biomarkers. This point was not clearly stated in the conference call. My first impression back in Sept. was that the lower sensitivity was obtained using the same microRNA biomarkers that were used in the first set of 128 samples. Overall, I see this as positive.

Could the "pregnancy-related" proof-of-concept be associated with preeclampsia and preterm labor? I remember these two conditions mentioned in ROSG announcements in 2007.